These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4085543)

  • 21. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possible involvement of serotonin receptors in the facilitatory effect of a hallucinogenic phenethylamine on single facial motoneurons.
    Penington NJ; Reiffenstein RJ
    Can J Physiol Pharmacol; 1986 Oct; 64(10):1302-9. PubMed ID: 3801984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT2 receptors in the nucleus tractus solitarius: characterisation and role in cardiovascular regulation in the rat.
    Merahi N; Orer HS; Laguzzi R
    Brain Res; 1992 Mar; 575(1):74-8. PubMed ID: 1504784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of [3H]5-HT binding to rat brain membranes by psychotomimetic amphetamines.
    De Jong AP; Huggins F; Fournier D; Makriyannis A
    Eur J Pharmacol; 1982 Sep; 83(3-4):305-8. PubMed ID: 7173311
    [No Abstract]   [Full Text] [Related]  

  • 25. Serotonin excitation of facial motoneurons: receptor subtype characterization.
    Rasmussen K; Aghajanian GK
    Synapse; 1990; 5(4):324-32. PubMed ID: 2360199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens.
    Lyon RA; Titeler M; Seggel MR; Glennon RA
    Eur J Pharmacol; 1988 Jan; 145(3):291-7. PubMed ID: 3350047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

  • 28. 5-HT2 receptors, roles and regulation.
    Leysen JE; Pauwels PJ
    Ann N Y Acad Sci; 1990; 600():183-91; discussion 192-3. PubMed ID: 2252309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic and dopaminergic involvement in the mechanism of action of R-(-)-2,5-dimethoxy-4-bromoamphetamine (DOB) in cats.
    Rusterholz DB; Spratt JL; Long JP; Kelly TF
    Life Sci; 1978 Oct; 23(14):1499-506. PubMed ID: 713706
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
    Nichols DE; Hoffman AJ; Oberlender RA; Riggs RM
    J Med Chem; 1986 Feb; 29(2):302-4. PubMed ID: 3950910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological characterization of 5-hydroxytryptamine2 receptors in the rat medial prefrontal cortex.
    Ashby CR; Jiang LH; Kasser RJ; Wang RY
    J Pharmacol Exp Ther; 1990 Jan; 252(1):171-8. PubMed ID: 2137174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of rigid analogues to probe hallucinogen receptors.
    Nichols DE; Weintraub HJ; Pfister WR; Yim GK
    NIDA Res Monogr; 1978; (22):70-83. PubMed ID: 101889
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
    Pranzatelli MR
    Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Spüler M; Nichols DE
    Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DOM and related 2,5-dimethoxy-4-alkylphenylisopropylamines: behavioral and serotonin receptor properties.
    Glennon RA; Doot DL; Young R
    Pharmacol Biochem Behav; 1981 Mar; 14(3):287-92. PubMed ID: 7232455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.
    Glennon RA; Rosecrans JA; Young R
    Med Res Rev; 1983; 3(3):289-340. PubMed ID: 6350763
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
    Glennon RA; Young R; Benington F; Morin RD
    J Med Chem; 1982 Oct; 25(10):1163-8. PubMed ID: 7143352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity.
    Glennon RA; Young R; Jacyno JM
    Biochem Pharmacol; 1983 Apr; 32(7):1267-73. PubMed ID: 6573879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines.
    Glennon RA; Young R; Jacyno JM; Slusher M; Rosecrans JA
    Eur J Pharmacol; 1983 Jan; 86(3-4):453-9. PubMed ID: 6572591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenylakylamines with potential psychotherapeutic utility. 1. 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)butane.
    Standridge RT; Howell HG; Gylys JA; Partyka RA; Shulgin AT
    J Med Chem; 1976 Dec; 19(12):1400-4. PubMed ID: 1003425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.